Carvedilol Tablet, Film Coated
Product Images NDC 72789-440

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 72789-440). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789440 Label (72789440)

Packaging label for Carvedilol USP 25 mg film-coated tablets, containing 180 tablets per bottle. The label displays the NDC 72789-440-93 and is manufactured by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. It includes dosage reminders, a warning to keep out of reach of children, and batch details with expiration date 04/2025.*

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Tab Usp Figure1)

A line chart depicting percent mortality over a 24-month period comparing Carvedilol versus placebo. The x-axis represents months from 0 to 24, and the y-axis shows percent mortality from 0 to 30. Two curves are labeled 'Carvedilol' and 'Placebo,' with the Carvedilol curve consistently lower. A p-value of 0.0014 is indicated on the graph.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Tab Usp Figure2)

A forest plot chart depicting hazard ratios for various subgroups including sex, age, race, diabetic and ischemic status, heart rate categories, systolic blood pressure levels, and spironolactone use. The horizontal axis represents hazard ratios ranging from 0.0 to 2.0, with a vertical reference line at 1.0. Each subgroup is marked with a point estimate and confidence intervals showing the relative risk compared to the reference.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Tab Usp Figure3)

A Kaplan-Meier survival curve displaying percent mortality on the y-axis versus time in months on the x-axis, comparing Carvedilol to placebo. The plot shows lower mortality percent for Carvedilol compared to placebo over 24 months, with a statistical p-value of 0.03 indicated.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Tab Usp Figure4)

A forest plot displaying hazard ratios for various subgroups of patients, including age, sex, timing of post-myocardial infarction, prior beta-blocker use, Killip class, thrombolytic status, percutaneous transluminal coronary angioplasty (PTCA) for MI, congestive heart failure (CHF) status, diuretic use during MI, angina, hypertension, diabetes, heart rate, and systolic blood pressure (SBP). The plot compares hazard ratios with confidence intervals for these factors, with a reference line at 1.0 representing no effect.*

FDA Label Image

Carvedilol Chemical Structure (Carvedilol Tab Usp Structure)

Chemical structure of Carvedilol depicting its molecular components, including aromatic rings, methoxy groups, hydroxyl groups, and an ether linkage, consistent with the active ingredient in Carvedilol tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.